Board & Leadership
The Management Team
Andrew Harrison
Andrew Harrison is an experienced CEO and Non-Executive Director of both publicly listed and private companies, across a range of industries, including radiology and medical artificial intelligence.
He has extensive experience in capital market transactions, technology commercialisation, local and international mergers and acquisitions, and strategic restructuring and turnaround. He has substantial international experience including in European, US, and Chinese markets. Andrew Harrison also served on the Board of Enlitic LLC a world leading US based medical AI company.
Dr. Wenjie Pang, PhD
Dr. Wenjie Pang built a successful career in China, researching magnetism in different forms. He has over 30 years of experience within different science and technology sectors.
He joined the University of Western Australia as a visiting research fellow in the Department of Physics. After an International Scholarship to study for his PhD and some time at the University of Colorado in the US, Dr Pang became one of the first employees of Resonance Health in 2005. Wenjie’s roles in the company have been pivotal and varied. He has been overseeing FerriScan® technology and is heavily involved in R&D projects as well as collaboration with external research partners. To make his own lifestyle more carbon neutral, he cycles to work and returns home with headwind almost on a daily basis.
Benjamin Carruthers
Benjamin Carruthers has over 20 years of experience in advisory, restructuring and turnaround in listed and private entities across a range of industries including mining and resources, services, retail, manufacturing, aquaculture and marine, education and training, and franchising.
Having commenced and spent most of his career in the chartered accounting environment, he was an Executive Director at KordaMentha which is a leading national advisory and investment firm focused on assisting clients throughout their lifecycle. He has extensive experience in M&A transactions, due diligence, modelling, and financial management.
Narelle Mounsey
Narelle is an accomplished HR leader with 20 years of experience in managing people and culture across various industries. She has successfully led HR teams in Australia, Indonesia, and the USA, and is also a certified coach and facilitator.
Narelle has been with Resonance Health for over three years and is dedicated to building high-performing teams.
Muhammad Hassnain
Muhammad has over 7 years’ experience in the medical device manufacturing industry, with a focus on Project Management, Quality Assurance and Regulatory Compliance.
He has previously project-managed the successful redevelopment of a single-use sterile medical device while meeting and exceeding all quality and regulatory requirements. He joined the Resonance Health team in 2022 and has taken steps to identify and implement a number of critical changes to ensure continued high-quality standards across all areas of the organisation. Currently, Muhammad leads the Quality Assurance and Regulatory Affairs team.
Chad Tondut
Chad Tondut is Vice President, Medical Devices at Resonance Health, responsible for the strategic leadership and delivery of the company’s SaMD portfolio. He oversees SaMD development, Service Centre operations, and Quality Assurance & Regulatory Affairs, ensuring products are clinically safe, customer-focused, and compliant with relevant regulatory standards.
Chad has been with Resonance Health since 2017, holding a range of roles across the organisation. He now leads cross-functional teams to drive innovation, manage budgets and resources, and deliver new and improved solutions across the full lifecycle.
Jun Chai
Jun brings 10 years of experience in research and product development, as well as operations in the personal care industry. Jun joined Resonance in 2018, bringing with her a background in Nanotechnology Science (Hons) along with a varied skillset in manufacturing.
Jun became the Service Centre Manager in early 2022. Leading a team of 12, she now oversees all operational activities, including MRI diagnostic image analyses services for over 200 MRI centres per year. She inspires a strong passion in ensuring the highest quality of services and results, upholding the interests of all clinicians and patients.
Dr. Helen Pavitt
Gavin Pinto
Gavin is Chief Technology Officer at Resonance Health, responsible for the company’s technology strategy and for leading the delivery of secure, scalable platforms across its medical imaging and diagnostics business. He oversees software engineering, quality control, data architecture, and IT infrastructure, embedding cybersecurity-by-design and web-first, API-led practices to ensure systems align with clinical, regulatory, and commercial requirements.
With over 20 years’ experience in specialist health and diagnostics technology, Gavin joined the company in 2004 as part of the original team responsible for securing the regulatory approval of FerriScan. Since then, he has worked on numerous regulatory submission projects for multiple Software as a Medical Device (SaMD) products, contributing to the technical and quality foundations that underpin successful clearances. His strong regulatory alignment-including ISO 13485 and IEC 62304-helps ensure solutions meet safety, compliance, and performance expectations across the full product lifecycle.
The Board
Aaron Brinkworth
Aaron had a 22-year career with Gilead Sciences, Inc. (Nasdaq: GILD) (Gilead) during which time the company grew from a small biotech-pharma company to a multi-billion-dollar global company with annual sales of over USD $27 billion.
He held several commercial, licensing, and patient access roles at Gilead, including that of Executive Director – Global Patient Solutions, where he was responsible for commercial and access strategies for emerging markets. He led Gilead’s commercial and access operations in the Asia Pacific (APAC) where he managed a geographically dispersed team and partners across 31 APAC countries including China, India, and Vietnam. He completed their Snr Leadership Development Program and was recognised with multiple awards. He has a Bachelor’s degree in Health Sciences from Edith Cowan University, and has served on the Board of the Royal Surf Lifesaving Society of Western Australia since 2020. He is a graduate of the AICD Company Directors course and maintains active membership of the AICD.
Andrew Harrison
Andrew Harrison is an experienced CEO and Non-Executive Director of both publicly listed and private companies, across a range of industries, including radiology and medical artificial intelligence.
He has extensive experience in capital market transactions, technology commercialisation, local and international mergers and acquisitions, and strategic restructuring and turnaround. He has substantial international experience including in European, US, and Chinese markets. Andrew Harrison also served on the Board of Enlitic LLC a world leading US based medical AI company.
Mitchell Wells
Mitchell is an experienced senior executive and a qualified lawyer with commercial and legal experience in Australia, the United States and the United Kingdom.
He has served as a director and worked as a senior executive of listed public and private companies including ASX and Nasdaq listed companies. He has international management experience in several industries, including as project manager and lawyer for AEG Europe and The O2 in London, UK. Prior to that, he was legal counsel for London 2012 which successfully bid to host the 2012 Olympic Games. He holds Bachelor degrees in Law and Commerce and a Diploma of Aviation. He joined Resonance Health in 2017 as legal consultant. He has served as Chair of two not-for-profit organisations.
Simon Panton
Simon has been a major shareholder of Resonance Health since 2008 and joined the board in 2009, as he is a strong believer in liver health technologies.
He started and ran his own successful small business for over 15 years and brings skills in business and marketing. He has experience in the property industry, financial markets, and the acquisition and disposal of investments. He currently manages assets and projects associated within family holdings and was a previous Non-Executive Director of 4DS Ltd.
Dr. Travis Baroni, PhD
Dr. Travis Baroni has broad experience across different sectors: industrial research, commercialisation of technology, asset valuations, and investment banking services.
He has been a manager of innovation development and technology strategy in a large company setting, as well as an active investor in early-stage investments. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research, and valuations to clients.
Dr. David Fuller
Dr. Fuller is a qualified medical doctor and pharmacist with over 3 decades of international experience in drug development and commercialization, especially in the therapeutic areas of oncology, renal medicine, neurology and anti-infectives.
Dr Fuller has a proven track record of creating value across large and small-cap environments and has honed his commercial management, business development, and corporate oversight skills through managing his own businesses, as well as holding senior management and Board roles in both private and ASX listed companies.